In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging

NeuroImage

Volumn 148, Issue , 2017, Pages 296-304

  Fagan, Anne M ^c,c   Hassenstab, Jason ^c,c   Cairns, Nigel J ^c,c   Morris, John C ^c,c   Christensen, Jon J ^b   Yablonskiy, Dmitriy A ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; GEPCI; MRI; Pathology; PET

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; AMYLOID BETA PROTEIN;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN TISSUE; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; FEMALE; GOLD STANDARD; GRADIENT ECHO PLURAL CONTRAST IMAGING; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; MALE; MEDIAL TEMPORAL LOBE; MENTAL HEALTH; MENTAL PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRECLINICAL STUDY; PRECUNEUS; PROTEIN CEREBROSPINAL FLUID LEVEL; PSYCHOMETRY; QUANTITATIVE ASSAY; ATROPHY; BRAIN; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; ECHO PLANAR IMAGING; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PARAHIPPOCAMPAL GYRUS; PATHOLOGY; PRODROMAL SYMPTOM; REFERENCE VALUE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; BRAIN; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; ECHO-PLANAR IMAGING; FEMALE; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARAHIPPOCAMPAL GYRUS; POSITRON-EMISSION TOMOGRAPHY; PRODROMAL SYMPTOMS; REFERENCE VALUES;

EID: 85010651427     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2016.12.026     Document Type: Article

References (71)

1. Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, P.J., Carrillo, M.C., Thies, B., Phelps, C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 7:3 (2011), 270–279.
2. Arnold, S.E., Hyman, B.T., Flory, J., Damasio, A.R., Van Hoesen, G.W., The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1:1 (1991), 103–116.
3. Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M., Holtzman, D.M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P.S., Ghetti, B., Klunk, W.E., McDade, E., Martins, R.N., Masters, C.L., Mayeux, R., Ringman, J.M., Rossor, M.N., Schofield, P.R., Sperling, R.A., Salloway, S., Morris, J.C., Dominantly inherited Alzheimer N. clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367:9 (2012), 795–804.
4. Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.) 57:1 (1995), 289–300.
5. Benveniste, H., Einstein, G., Kim, K.R., Hulette, C., Johnson, G.A., Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc. Natl. Acad. Sci. 96:24 (1999), 14079–14084.
6. Benzinger, T.L., Blazey, T., Jack, C.R., Jr, Koeppe, R.A., Su, Y., Xiong, C., Raichle, M.E., Snyder, A.Z., Ances, B.M., Bateman, R.J., Cairns, N.J., Fagan, A.M., Goate, A., Marcus, D.S., Aisen, P.S., Christensen, J.J., Ercole, L., Hornbeck, R.C., Farrar, A.M., Aldea, P., Jasielec, M.S., Owen, C.J., Xie, X., Mayeux, R., Brickman, A., McDade, E., Klunk, W., Mathis, C.A., Ringman, J., Thompson, P.M., Ghetti, B., Saykin, A.J., Sperling, R.A., Johnson, K.A., Salloway, S., Correia, S., Schofield, P.R., Masters, C.L., Rowe, C., Villemagne, V.L., Martins, R., Ourselin, S., Rossor, M.N., Fox, N.C., Cash, D.M., Weiner, M.W., Holtzman, D.M., Buckles, V.D., Moulder, K., Morris, J.C., Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 110:47 (2013), E4502–E4509.
7. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82:4 (1991), 239–259.
8. Buckner, R.L., Snyder, A.Z., Shannon, B.J., LaRossa, G., Sachs, R., Fotenos, A.F., Sheline, Y.I., Klunk, W.E., Mathis, C.A., Morris, J.C., Mintun, M.A., Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci.: Off. J. Soc. Neurosci. 25:34 (2005), 7709–7717.
9. Chamberlain, R., Reyes, D., Curran, G.L., Marjanska, M., Wengenack, T.M., Poduslo, J.F., Garwood, M., Jack, C.R., Comparison of amyloid plaque contrast generated by T2-weighted, T 2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer's disease. Magn. Reson. Med. 61:5 (2009), 1158–1164.
10. Dickerson, B.C., Stoub, T.R., Shah, R.C., Sperling, R.A., Killiany, R.J., Albert, M.S., Hyman, B.T., Blacker, D., Detoledo-Morrell, L., Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 76:16 (2011), 1395–1402.
11. Duyn, J.H., The future of ultra-high field MRI and fMRI for study of the human brain. NeuroImage 62:2 (2012), 1241–1248.
12. Elman, J.A., Oh, H., Madison, C.M., Baker, S.L., Vogel, J.W., Marks, S.M., Crowley, S., O'Neil, J.P., Jagust, W.J., Neural compensation in older people with brain amyloid-beta deposition. Nat. Neurosci. 17:10 (2014), 1316–1318.
13. Fagan, A.M., Csernansky, C.A., Morris, J.C., Holtzman, D.M., The search for antecedent biomarkers of Alzheimer's disease. J. Alzheimer's disease: JAD 8:4 (2005), 347–358.
14. Fjell, A.M., McEvoy, L., Holland, D., Dale, A.M., Walhovd, K.B., What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Progress. Neurobiol. 117 (2014), 20–40.
15. Gomez-Isla, T., Price, J.L., McKeel, D.W. Jr., Morris, J.C., Growdon, J.H., Hyman, B.T., Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci.: Off. J. Soc. Neurosci. 16:14 (1996), 4491–4500.
16. Hardy, J., Allsop, D., Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12:10 (1991), 383–388.
17. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:5580 (2002), 353–356.
18. Hardy, J.A., Higgins, G.A., Alzheimer's disease: the amyloid cascade hypothesis. Science 256:5054 (1992), 184–185.
19. He, X., Zhu, M., Yablonskiy, D.A., Validation of oxygen extraction fraction measurement by qBOLD technique. Magn. Reson. Med. 60:4 (2008), 882–888.
20. Hoesen, G.W.V., The human parahippocampal region in Alzheimer's disease, dementia, and ageing. Witter, M.P., Wouterlood, F.G., (eds.) The Parahippocampal Region: Organization and Role in Cognitive Function, 2002, Oxford University Press, Oxford, New York.
21. Hyman, B.T., Van Hoesen, G.W., Damasio, A.R., Barnes, C.L., Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225:4667 (1984), 1168–1170.
22. Ikonomovic, M.D., Klunk, W.E., Abrahamson, E.E., Mathis, C.A., Price, J.C., Tsopelas, N.D., Lopresti, B.J., Ziolko, S., Bi, W., Paljug, W.R., Debnath, M.L., Hope, C.E., Isanski, B.A., Hamilton, R.L., DeKosky, S.T., Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131:Pt 6 (2008), 1630–1645.
23. Jack, C.R., Jr, Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9:1 (2010), 119–128.
24. Jack, C.R. Jr., Petersen, R.C., Xu, Y., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, B.F., Tangalos, E.G., Kokmen, E., Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55:4 (2000), 484–489.
25. Jenkinson, M., Bannister, P., Brady, M., Smith, S., Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17:2 (2002), 825–841.
26. Jenkinson, M., Beckmann, C.F., Behrens, T.E.J., Woolrich, M.W., Smith, S.M., FSL. NeuroImage 62:2 (2012), 782–790.
27. Johnson, D.K., Storandt, M., Morris, J.C., Langford, Z.D., Galvin, J.E., Cognitive profiles in dementia: alzheimer disease vs healthy brain aging. Neurology 71:22 (2008), 1783–1789.
28. Juottonen, K., Lehtovirta, M., Helisalmi, S., Riekkinen, P.J., Sr, Soininen, H., Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele. J Neurol. Neurosurg. Psychiatry 65:3 (1998), 322–327.
29. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergstrom, M., Savitcheva, I., Huang, G.F., Estrada, S., Ausen, B., Debnath, M.L., Barletta, J., Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A., Langstrom, B., Imaging brain amyloid in Alzheimer's disease with pittsburgh compound-B. Ann. Neurol. 55:3 (2004), 306–319.
30. Lee, S.-P., Falangola, M.F., Nixon, R.A., Duff, K., Helpern, J.A., Visualization of β-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn. Reson. Med. 52:3 (2004), 538–544.
31. Luo, J., Jagadeesan, B.D., Cross, A.H., Yablonskiy, D.A., Gradient echo plural contrast imaging – signal model and derived contrasts: T2*, T1, Phase, SWI, T1f, FST2*and T2*-SWI. NeuroImage 60:2 (2012), 1073–1082.
32. Luo, J., Yablonskiy, D.A., Hildebolt, C.F., Lancia, S., Cross, A.H., Gradient echo magnetic resonance imaging correlates with clinical measures and allows visualization of veins within multiple sclerosis lesions. Mult. Scler. 20:3 (2014), 349–355.
33. Maier, F.C., Keller, M.D., Bukala, D., Bender, B., Mannheim, J.G., Brereton, I.M., Galloway, G.J., Pichler, B.J., Quantification of beta-amyloidosis and rCBF with dedicated PET, 7 T MR imaging, and high-resolution microscopic MR imaging at 16.4 T in APP23 Mice. J. Nucl. Med.: Off. Publ. Soc. Nucl. Med. 56:10 (2015), 1593–1599.
34. Mamah, D., Wen, J., Luo, J., Ulrich, X., Barch, D.M., Yablonskiy, D., Subcomponents of brain T2* relaxation in schizophrenia, bipolar disorder and siblings: a Gradient Echo Plural Contrast Imaging (GEPCI) study. Schizophr. Res., 2015.
35. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, Jr. C.R., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S., Phelps, C.H., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's. Dement. 7:3 (2011), 263–269.
36. Meadowcroft, M.D., Connor, J.R., Smith, M.B., Yang, Q.X., MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J. Magn. Reson. Imaging 29:5 (2009), 997–1007.
37. Mintun, M.A., Larossa, G.N., Sheline, Y.I., Dence, C.S., Lee, S.Y., Mach, R.H., Klunk, W.E., Mathis, C.A., DeKosky, S.T., Morris, J.C., [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:3 (2006), 446–452.
38. Mitchell, T.W., Mufson, E.J., Schneider, J.A., Cochran, E.J., Nissanov, J., Han, L.Y., Bienias, J.L., Lee, V.M., Trojanowski, J.Q., Bennett, D.A., Arnold, S.E., Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann. Neurol. 51:2 (2002), 182–189.
39. Morris, J.C., The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:11 (1993), 2412–2414.
40. Morris, J.C., Roe, C.M., Grant, E.A., Head, D., Storandt, M., Goate, A.M., Fagan, A.M., Holtzman, D.M., Mintun, M.A., Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66:12 (2009), 1469–1475.
41. Morris, J.C., Aisen, P.S., Bateman, R.J., Benzinger, T.L., Cairns, N.J., Fagan, A.M., Ghetti, B., Goate, A.M., Holtzman, D.M., Klunk, W.E., McDade, E., Marcus, D.S., Martins, R.N., Masters, C.L., Mayeux, R., Oliver, A., Quaid, K., Ringman, J.M., Rossor, M.N., Salloway, S., Schofield, P.R., Selsor, N.J., Sperling, R.A., Weiner, M.W., Xiong, C., Moulder, K.L., Buckles, V.D., Developing an international network for Alzheimer research: the dominantly Inherited Alzheimer network. Clin. Investig. (Lond.) 2:10 (2012), 975–984.
42. Mugler, J.P., Brookeman, J.R., Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MP RAGE). Magn. Reson. Med. 15:1 (1990), 152–157.
43. Patel, K.R., Luo, J., Alvarez, E., Piccio, L., Schmidt, R.E., Yablonskiy, D.A., Cross, A.H., Detection of cortical lesions in multiple sclerosis: a new imaging approach. Mult. Scler. J. – Exp. Transl. Clin., 2015, 1.
44. Price, J.C., Klunk, W.E., Lopresti, B.J., Lu, X., Hoge, J.A., Ziolko, S.K., Holt, D.P., Meltzer, C.C., DeKosky, S.T., Mathis, C.A., Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J. Cereb. 25:11 (2005), 1528–1547.
45. Price, J.L., Morris, J.C., Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann. Neurol. 45:3 (1999), 358–368.
46. Price, J.L., Ko, A.I., Wade, M.J., Tsou, S.K., McKeel, D.W., Morris, J.C., Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 58:9 (2001), 1395–1402.
47. Price, J.L., McKeel, D.W., Jr, Buckles, V.D., Roe, C.M., Xiong, C., Grundman, M., Hansen, L.A., Petersen, R.C., Parisi, J.E., Dickson, D.W., Smith, C.D., Davis, D.G., Schmitt, F.A., Markesbery, W.R., Kaye, J., Kurlan, R., Hulette, C., Kurland, B.F., Higdon, R., Kukull, W., Morris, J.C., Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 30:7 (2009), 1026–1036.
48. Quirk, J.D., Sukstanskii, A.L., Bretthorst, G.L., Yablonskiy, D.A., Optimal decay rate constant estimates from phased array data utilizing joint Bayesian analysis. J. Magn. Reson 198:1 (2009), 49–56.
49. Raichle, M.E., MacLeod, A.M., Snyder, A.Z., Powers, W.J., Gusnard, D.A., Shulman, G.L., A default mode of brain function. Proc. Natl. Acad. Sci. U. S. A. 98:2 (2001), 676–682.
50. Reiman, E.M., Langbaum, J.B., Tariot, P.N., Lopera, F., Bateman, R.J., Morris, J.C., Sperling, R.A., Aisen, P.S., Roses, A.D., Welsh-Bohmer, K.A., Carrillo, M.C., Weninger, S., CAP – advancing the evaluation of preclinical Alzheimer disease treatments. Nat. Rev. Neurol. 12:1 (2016), 56–61.
51. Rentz, D.M., Locascio, J.J., Becker, J.A., Moran, E.K., Eng, E., Buckner, R.L., Sperling, R.A., Johnson, K.A., Cognition, reserve, and amyloid deposition in normal aging. Ann. Neurol. 67:3 (2010), 353–364.
52. Reuter, M., Schmansky, N.J., Rosas, H.D., Fischl, B., Within-subject template estimation for unbiased longitudinal image analysis. NeuroImage 61:4 (2012), 1402–1418.
53. Sati, P., Cross, A.H., Luo, J., Hildebolt, C.F., Yablonskiy, D.A., In vivo quantitative evaluation of brain tissue damage in multiple sclerosis using gradient echo plural contrast imaging technique. NeuroImage 51:3 (2010), 1089–1097.
54. Scharfman, H.E., Witter, M.P., Schwarcz, R., 2000. Preface. Annals of the New York Academy of Sciences; 911(1): ix-xiii.
55. Schuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L.M., Trojanowski, J.Q., Thompson, P.M., Jack, C.R. Jr., Weiner, M.W., Alzheimer's Disease Neuroimaging, I., MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 132:Pt 4 (2009), 1067–1077.
56. Selkoe, D.J., Alzheimer's disease. In the beginning. Nature 354:6353 (1991), 432–433.
57. Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., Iwatsubo, T., Jack, C.R., Jr, Kaye, J., Montine, T.J., Park, D.C., Reiman, E.M., Rowe, C.C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M.C., Thies, B., Morrison-Bogorad, M., Wagster, M.V., Phelps, C.H., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement.: J. Alzheimer's Assoc. 7:3 (2011), 280–292.
58. Su, Y., D'Angelo, G.M., Vlassenko, A.G., Zhou, G., Snyder, A.Z., Marcus, D.S., Blazey, T.M., Christensen, J.J., Vora, S., Morris, J.C., Mintun, M.A., Benzinger, T.L., Quantitative analysis of PiB-PET with FreeSurfer ROIs. PloS one, 8(11), 2013, e73377.
59. Thangavel, R., Van Hoesen, G.W., Zaheer, A., Posterior parahippocampal gyrus pathology in Alzheimer's disease. Neuroscience 154:2 (2008), 667–676.
60. Ulrich, X., Yablonskiy, D.A., Separation of cellular and BOLD contributions to T2* signal relaxation. Magn. Reson. Med., 2015.
61. Vlassenko, A.G., Vaishnavi, S.N., Couture, L., Sacco, D., Shannon, B.J., Mach, R.H., Morris, J.C., Raichle, M.E., Mintun, M.A., Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc. Natl. Acad. Sci. U. S. A. 107:41 (2010), 17763–17767.
62. Wang, X., Sukstanskii, A.L., Yablonskiy, D.A., Optimization strategies for evaluation of brain hemodynamic parameters with qBOLD technique. Magn. Reson. Med. 69:4 (2013), 1034–1043.
63. Wen, J., Cross, A.H., Yablonskiy, D.A., On the role of physiological fluctuations in quantitative gradient echo MRI: implications for GEPCI, QSM, and SWI. Magn. Reson. Med., 2014.
64. Wen, J., Yablonskiy, D.A., Luo, J., Lancia, S., Hildebolt, C., Cross, A.H., Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI. NeuroImage: Clin. 9 (2015), 164–175.
65. Wengenack, T.M., Reyes, D.A., Curran, G.L., Borowski, B.J., Lin, J., Preboske, G.M., Holasek, S.S., Gilles, E.J., Chamberlain, R., Marjanska, M., Jack, C.R., Jr, Garwood, M., Poduslo, J.F., Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. NeuroImage 54:1 (2011), 113–122.
66. Wirth, M., Madison, C.M., Rabinovici, G.D., Oh, H., Landau, S.M., Jagust, W.J., Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. J. Neurosci.: Off. J. Soc. Neurosci. 33:13 (2013), 5553–5563.
67. Yablonskiy, D.A., Quantitation of intrinsic magnetic susceptibility-related effects in a tissue matrix. Phantom study. Magn. Reson. Med. 39:3 (1998), 417–428.
68. Yablonskiy, D.A., Haacke, E.M., Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn. Reson. Med. 32:6 (1994), 749–763.
69. Yablonskiy, D.A., Sukstanskii, A.L., Luo, J., Wang, X., Voxel spread function method for correction of magnetic field inhomogeneity effects in quantitative gradient-echo-based MRI. Magn. Reson. Med. 70:5 (2013), 1283–1292.
70. Yablonskiy DA. Quntitative T2 contrast with Gradient Echoes. in: Proceedings of the 8th Annual Meeting of the International Society for Magnetic Resonance in Medicine. Denver, Colorado, 2000.
71. Zhao, Y., Wen, J., Cross, A.H., Yablonskiy, D.A., On the relationship between cellular and hemodynamic properties of the human brain cortex throughout adult lifespan. NeuroImage 133 (2016), 417–429.